PAM
CRBP icon

Panagora Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Panagora Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-350
Closed -$19K – 2828
2020
Q3 		$19K Hold
350
– – ﹤0.01% 2218
2020
Q2 		$88K Hold
350
– – ﹤0.01% 1825
2020
Q1 		$55K Buy
+350
New +$59.2K ﹤0.01% 1859

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Panagora Asset Management's CRBP Position: Q4 2020 in Review

Panagora Asset Management sold out of Corbus Pharmaceuticals (CRBP) in Q4 2020, closing a stake of 350 shares — an estimated $19K sold.

Panagora Asset Management first reported a position in CRBP in Q1 2020 and held it in 3 quarters. The position peaked at $88K in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q4 2020.

  • Panagora Asset Management reported no remaining Corbus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Panagora Asset Management sold 350 Corbus Pharmaceuticals shares in Q4 2020, an estimated $19K.
  • Panagora Asset Management first reported a position in Corbus Pharmaceuticals in Q1 2020 and held it in 3 quarters.
  • Panagora Asset Management's Corbus Pharmaceuticals position peaked at $88K in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2020.

Based on Panagora Asset Management's 13F filing for Q4 2020, filed 10 Feb 2021.